Skip to content

Efficacy and safety of Qi Wei Antipruritic Lotion for mild-to-moderate atopic dermatitis: protocol of a randomised, double-blind, placebo-controlled,single-centre trial

A clinical efficacy study on the external application of Qi Wei Antipruritic Powder for atopic dermatitis based on the Transdermal Drug Delivery Systems

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002291
Enrollment
Unknown
Registered
2025-11-21
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

treatment group (receiving wet compresses with Qi Wei Antipruritic Lotion):The treatment group received wet compresses with Qi Wei Antipruritic Lotion.Applied twice daily for 20 minutes per session.
control group (receiving wet compresses with a placebo solution):The control group received wet compresses with placebo Lotion.Applied twice daily for 20 minutes per session.

Sponsors

Hospital Affiliated to Chengdu University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Meets the diagnostic criteria for atopic dermatitis as described above, confirmed as mild to moderate AD (SCORAD score 0–50) (2)Aged 18–65 years, no gender restrictions (3)Willing to undergo and comply with topical medication wet dressings (4)Voluntary participants will sign a written informed consent form

Exclusion criteria

Exclusion criteria: (1) Patients with severe AD (SCORAD score > 50); (2) Allergic to the test drug or any of its components; (3) Patients in the lactation period, pregnancy, suspected pregnancy, or planning to become pregnant during the treatment period; (4) Patients with immunodeficiency or autoimmune diseases, or those with underlying diseases (such as diabetes), which may have a potential impact on the efficacy and prognosis of this study; (5) Lesion sites on the skin of the subjects have wounds, abrasions, tattoos, or other conditions that may affect the determination of test results; (6) Those who cannot actively cooperate, have poor compliance, incomplete data collection, or participate in other clinical trials during the study.

Design outcomes

Primary

MeasureTime frame
Scoring Atopic Dermatitis;

Secondary

MeasureTime frame
Clinical dermatologist evaluation form;The Dermatology Life Quality Index (DLQI) assessment form;

Countries

China

Contacts

Public ContactCheng Hongbin

Hospital Affiliated to Chengdu University of TCM

Hongbincheng2007@126.com13880848134

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026